Salivary
Biomarker
C-C motif chemokine ligand 20
CCL20
Fusobacterium
OSCC
microbiome
oral squamous cell carcinoma
saliva
Journal
Cancer genomics & proteomics
ISSN: 1790-6245
Titre abrégé: Cancer Genomics Proteomics
Pays: Greece
ID NLM: 101188791
Informations de publication
Date de publication:
Historique:
received:
26
12
2020
revised:
14
01
2021
accepted:
20
01
2021
entrez:
20
2
2021
pubmed:
21
2
2021
medline:
29
9
2021
Statut:
ppublish
Résumé
This study investigated the utility of C-C motif chemokine ligand 20 (CCL20) expression in saliva as a biomarker for oral squamous cell carcinoma (OSCC) and also examined the associated microbiome. The study group included patients with OSCC or oral potentially malignant disorder (OPMD), and healthy volunteers (HVs). microarray and qRT-PCR were used to compare salivary CCL20 expression levels among groups. Data on CCL20 levels in oral cancer tissues and normal tissues were retrieved from a public database and examined. Furthermore, next-generation sequencing was used to investigate the salivary microbiome. A significant increase in the expression level of CCL20 was observed in both OSCC tissues and saliva from patients with oral cancer. Fusobacterium was identified as the predominant bacteria in OSCC and correlated with CCL20 expression level. OSCC screening based on salivary CCL20 expression enabled successful differentiation between patients with OSCC and HVs. CCL20 expression may be a useful biomarker for OSCC.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
This study investigated the utility of C-C motif chemokine ligand 20 (CCL20) expression in saliva as a biomarker for oral squamous cell carcinoma (OSCC) and also examined the associated microbiome.
MATERIALS AND METHODS
METHODS
The study group included patients with OSCC or oral potentially malignant disorder (OPMD), and healthy volunteers (HVs). microarray and qRT-PCR were used to compare salivary CCL20 expression levels among groups. Data on CCL20 levels in oral cancer tissues and normal tissues were retrieved from a public database and examined. Furthermore, next-generation sequencing was used to investigate the salivary microbiome.
RESULTS
RESULTS
A significant increase in the expression level of CCL20 was observed in both OSCC tissues and saliva from patients with oral cancer. Fusobacterium was identified as the predominant bacteria in OSCC and correlated with CCL20 expression level. OSCC screening based on salivary CCL20 expression enabled successful differentiation between patients with OSCC and HVs.
CONCLUSION
CONCLUSIONS
CCL20 expression may be a useful biomarker for OSCC.
Identifiants
pubmed: 33608307
pii: 18/2/103
doi: 10.21873/cgp.20245
pmc: PMC7943213
doi:
Substances chimiques
Biomarkers, Tumor
0
CCL20 protein, human
0
Chemokine CCL20
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
103-112Informations de copyright
Copyright© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
Nat Rev Genet. 2012 Mar 13;13(4):260-70
pubmed: 22411464
Acta Otorhinolaryngol Ital. 2011 Dec;31(6):347-57
pubmed: 22323845
J Clin Oncol. 2015 Oct 10;33(29):3269-76
pubmed: 26351335
Genome Biol. 2011 Jun 24;12(6):R60
pubmed: 21702898
BMC Med Genomics. 2019 Jul 11;12(Suppl 5):101
pubmed: 31296229
Oral Dis. 2019 Jan;25(1):97-107
pubmed: 30169911
Oncotarget. 2015 Mar 30;6(9):7209-20
pubmed: 25797243
Anticancer Res. 2015 Dec;35(12):6577-81
pubmed: 26637872
Oncotarget. 2015 Sep 8;6(26):22613-23
pubmed: 26158901
Scand J Immunol. 2013 Sep;78(3):298-305
pubmed: 23790181
Front Immunol. 2015 May 05;6:214
pubmed: 25999952
J Surg Oncol. 2009 Dec 15;100(8):725-31
pubmed: 19722233
J Investig Clin Dent. 2019 Nov;10(4):e12445
pubmed: 31342659
Technol Cancer Res Treat. 2019 Jan 1;18:1533033819867354
pubmed: 31370775
Clin Cancer Res. 2016 Nov 15;22(22):5574-5581
pubmed: 27769987
Clin Transl Med. 2014 Feb 24;3(1):3
pubmed: 24564868
World J Gastroenterol. 2016 Jan 14;22(2):833-41
pubmed: 26811629
Carcinogenesis. 2018 May 28;39(6):778-787
pubmed: 29668903
J Periodontal Res. 2017 Jun;52(3):428-437
pubmed: 27549383
Anticancer Res. 2019 Nov;39(11):5953-5962
pubmed: 31704820
Eur J Oral Sci. 1996 Apr;104(2 ( Pt 1)):112-7
pubmed: 8804898
J Am Dent Assoc. 2001 Nov;132 Suppl:24S-29S
pubmed: 11803649
PLoS Pathog. 2014 Mar 27;10(3):e1003933
pubmed: 24676390
Oral Oncol. 2010 Jun;46(6):414-7
pubmed: 20400366
Arch Oral Biol. 2011 Dec;56(12):1506-13
pubmed: 21704302
Front Microbiol. 2018 May 03;9:862
pubmed: 29774014
Anticancer Res. 2018 Jan;38(1):113-120
pubmed: 29277763
Front Cell Infect Microbiol. 2020 Aug 07;10:403
pubmed: 32850498
J Oral Maxillofac Surg. 2003 Mar;61(3):285-91
pubmed: 12618965
Tumour Biol. 2016 Feb;37(2):1995-2005
pubmed: 26334621
Anticancer Res. 2019 Apr;39(4):1935-1942
pubmed: 30952736
Biomed Pharmacother. 2017 May;89:918-925
pubmed: 28292019
Arch Microbiol. 2021 Jan;203(1):137-152
pubmed: 32783067
Clin Microbiol Rev. 2013 Oct;26(4):781-91
pubmed: 24092855
Br J Oral Maxillofac Surg. 2005 Aug;43(4):281-4
pubmed: 15993279
CA Cancer J Clin. 2002 Jul-Aug;52(4):195-215
pubmed: 12139232
Ann Gastroenterol Surg. 2017 Jun 07;1(2):99-104
pubmed: 29863142
Cancer Prev Res (Phila). 2017 Jul;10(7):398-409
pubmed: 28483840
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
J Bacteriol. 2005 Aug;187(15):5330-40
pubmed: 16030227
J Pathol. 2012 Jan;226(2):148-57
pubmed: 21989643
In Vivo. 2020 Sep-Oct;34(5):2353-2361
pubmed: 32871760
Gerodontology. 2013 Sep;30(3):194-200
pubmed: 22607478
J Gastroenterol. 2019 Jan;54(1):33-41
pubmed: 30244399
J Gastrointest Surg. 2012 Apr;16(4):828-36
pubmed: 22072303
Curr Oral Health Rep. 2014 Jun 1;1(2):133-141
pubmed: 24883261